



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Loughney et al. I hereby certify that this paper is being deposited with the United States Postal Serial No.: 10 034,015 Service as first class mail, postage prepaid, in an envelope addressed to: Filed: December 20, 2001 Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on OB SEP SON THE CENTER TOO SOOS TO SEP SOOS For: Phosphodiesterase 10 this date:

Group Art: 1652 Date: September 22, 2003

Eric M. Brusca Reg. No. 52,664

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Examiner: Richard G. Hutson

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached PTO-1449 is hereby submitted by Applicants for consideration in connection with the above-identified patent application. With the exception of references A1 and A2 (Beavo et al and Fisher et al) which were cited by the Examiner in the parent application, copies of the cited documents have been previously filed and may be found in related applications United States Serial No.: 09/256,000, now U.S. Patent No. 6,350,603. This Information Disclosure Statement is not intended to be an admission that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

This statement and PTO-1449 form are submitted after receipt of a first Office Action in the above-identified patent application. Accordingly, the Applicants

file herewith a check in the amount of \$180.00. The Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

Ву

Eric M. Brusca (Reg. No. 52,664)

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606

September 22, 2003

(312) 474-6300

Form PTO-1449 (Modified)

SEP 2 4 2003

U.S. Department of Commerce Patent and Trademark Office

Atty: Docket No. 27866/37993 Serial No 10/034,015

		SEP Z 4 D	w 2	Patent and Trademark Office	27866/37993	10/034,	015
INFOD	እለ ል ገ	TON TOWER	CHDE	STATEMENT	Applicant Kate Loughney	4	
INFOR		(Use several shee			Filing Date 12-20-01	Group 1652	CT 00
							THE TOWN
			U.S. PA	TENT DOCUME	NTS		200
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,389,527	2-14-95	Beavo et al.	435	69.1	
	A2	5,922,595	7-13-99	Fisher et al.	435	320.1	
		<u></u>	<u> </u>				

FOREIGN PATENT DOCUMENTS									
Translation									
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No	
	В1	WO 91/09955	07-11-91	PCT					
	B2	WO 92/20808	11-26-92	PCT					
	В3	WO 94/12650	06-09-94	PCT					
	B4	WO 97/09433	03-13-97	PCT					
	B5	0 044 527 A1	7-15-81	ЕРО					

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C1	Anderson, "Human gene therapy," <i>Nature</i> , supplement to vol. 392, no. 6679, p. 25 (1998)
C2	Ausebel, et al., "Screening of Recombinant DNA Libraries," <u>Current Protocols in Molecular Biology</u> , John Wiley & Sons, pp. 6.0.3-6.4.10 (1994)

EX	AA	411	VIE	D

DATE CONSIDERED

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Aity. Docket No. 27866/37993 Senal No 10/034,015

INFORMA	TION BISCLOSURE STATEMENT	Applicant Kate Loughney			
INFORMA	(Use several sheets if necessary)	Filing Date 12-20-01	Group 1652 CT 3	N/Z	
			THE THE		
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Per		_	
C3	Avramopoulos, et al., "Linkage mapping or gene on human chromosome 21 using a DN region," <i>Hum. Genet.</i> 90 :566-568 (1993)				
C4	Beavo, "Cyclic Nucleotide Phosphodiestera Multiple Isoforms," <i>Physiol. Rev.</i> 75 :725-7		nplications of		
C5	Bolger, et al., "A Family of Human Phosph dunce Learning and Memory Gene Product Potential Targets for Antidepressant Drugs, (1993)	of Drosophila me	elanogaster Are		
C6	Bolger, et al., "Characterization of five diffalternatively spliced mRNAs from the huma PD34D gene," <i>Biochem. J.</i> 328 :539-548 (1)	an cAMP-specific			
C7	Bonne-Tamir, et al., "Linkage of Congenitato Chromosome 21q22.3," Am. J. Hum. Ge				
C8	Boolell, et al., "Sildenafil: an orally active phosphodiesterase inhibitor for the treatmer <i>Impotence Res.</i> 8 :47-50 (1996)		•		
С9	Bramlage, et al., "Designing ribozymes for <i>Trends in Biotech</i> 16 :434-438 (1998)	the inhibition of	gene expression,"	_	
C1	Cane, et al., "Harnessing the Biosynthetic of Mutations," <i>Science</i> 282 :63-68 (1998)	Code: Combinatio	ons, Permutations, and		
C1	1 Capecchi, "Altering the Genome by Homol 244 :1288-1292 (1989)	ogous Recombina	tion," Science		
C1	Charbonneau, et al., "Identification of a connucleotide phosphodiesterases from diverse 83:9308-9312 (1986)				
Cı	Collins, et al., "The Human β-Subunit of R Phosphodiesterase: Complete Retinal cDNA Expression in Brain," <i>Genomics</i> 13 :698-70-	Sequence and E			

EXAMINER

DATE CONSIDERED

Form PTO-1449 (Modified) OSURE STATEMENT INFORMATION DE

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty Docket No 27866/37993	Serial No 10/034,015				
INFORMATI	TRADE MARKET	Applicant Kate Loughney	Group 1652 The Top of timent Pages, etc.)				
IIII ORIVIIII	(Use several sheets if necessary)	Filing Date 12-20-01	Group 1652				
	CONTRACTOR OF THE CONTRACTOR O		7月1000000000000000000000000000000000000				
	OTHER DOCUMENTS (Including Au	uthor, Title, Date, Per	tinent Pages, etc.)				
C14	Coste, et al., "Characterization of a Novel I Phosphodiesterase," <i>Biochem. Pharmacol</i>						
C15	Delabar, et al., "Molecular Mapping of Two on Chromosome 21," Eur. J. Hum. Genet.		l l				
C16	Francis, et al., "Zinc Interactions and Consecutive Composition of						
C17	C17 Friedmann, "Progress Toward Human Gene Therapy," Science 244:1275-1281 (1989)						
C18	C18 Gibson, et al., "Ribozymes: Their Functions and Strategies for Their Use," <i>Mol. Biotech.</i> 7:125-137 (1997)						
C19	C19 Harbinson, et al., "The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects," <i>Eur. Respir. J.</i> 10:1008-1014 (1997)						
C20							
C21							
C22							
C23							
C24	Korenberg, et al., "Down syndrome phenot chromosomal imbalance," <i>Proc. Natl. Acad</i>						
C25	Lavrovsky, et al., "Therapeutic Potential an Oligonucleotides and Ribozymes," <i>Biochem</i>						

EXAMINER

DATE CONSIDERED

Form PTO-1449 (Modified) **OSURE STATEMENT**

U.S. Department of Commerce Patent and Trademark Office

Atty Docket No. Serial No 27866/37993

10/034,015

Applicant

Kate Loughney

Filing Date 12-20-01

TECH CENTED TOOS Group 1652

(Use several sheets if necessary)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C2	Lehninger, "The Amino Acid Building Blocks of Proteins," <u>Biochemistry</u> , Second Edition; Worth Publishers, Inc. NY·NY pp. 71-77 (1975)
C2	Loughney et al., "Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases*," <i>J. Biol Chem.</i> 271 :796-806 (1996)
C2	Loughney, et al., "Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods," Phosphodiesterase Inhibitors , Academic Press: New York, New York pp. 1-19 (1996)
C2	Manganiello, et al., "Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterases," <u>Isoenzymes of Cyclic Nucleotide Phosphodiesterases</u> , John Wiley and Sons, Ltd., pp. 87-116 (1990)
C3	Manganiello, et al., "Perspectives in Biochemistry and Biophysics Isoenzyme Families," <i>Arch. Biochem. Acta</i> 322 :1-13 (1995)
C3	Meacci, et al., "Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase," <i>Proc. Natl. Acad. Sci. (USA)</i> 89 :3721-3725 (1992)
C3	Michaeli, et al., "Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of cAMP Phosphodiesterase-deficient Saccharomyces cerevisiae*," J. Biol. Chem. 17:12925-12932 (1993)
C3	Miki, et al., "Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family," <i>Genomics</i> 36 :476-485 (1996)
C3	Miller, "Human gene therapy comes of age," <i>Nature</i> 357 :455-460 (1992)
C3	Munke, et al., "The Gene for Cystathionine β-Synthase (CBS) Maps to the Subtelomeric Region on Human Chromosome 21q and to Proximal Mouse Chromosome 17," <i>Hum. Genet.</i> 42 :550-559 (1988)

F	Y	A	M	IN	JF.	R

DATE CONSIDERED

Form PTO 1449 (Modified)



U.S. Department of Commerce Patent and Trademark Office

Atty Docket No. 27866/37993 Serial No 10/034,015

INFORMATION DISCI OSURE STATEMENT

	Patent and Trademark Office	27866/37993	10/034,015				
INFORMAT	TION DISCLOSURE STATEMENT	Applicant Kate Loughney	Group 1652	SE TE			
INFORMAT	(Use several sheets if necessary)	Filing Date 12-20-01	Group 1652	SE 30			
			7	103			
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Per	tinent Pages, etc.	190			
C36	Myers, "Will combinational chemistry deliving Biotechnol. 8:701-707 (1997)	ver real medicines	?" Curr. Opi	on.			
C37	Pittler, et al., "Molecular Characterization Photoreceptor cGMP Phosphodiesterase α-S of the Human Gene," <i>Genomics</i> 6:272-283	Subunit and Chror		alization			
C38							
C39	Podzuweit, et al., "Isozyme Selective Inhibition of cGMP-Stimulated Cyclic Nucleotide Phosphodiesterases by Erythro-9-(2-Hydroxy-3-Nonyl) Adenine," C Signaling 7:733-738 (1995)						
C40	Price, et al., "Expression of Heterologous l Using the ADH2 Promoter," Meth. Enzymo			vvisiae			
C41	Rosman, et al., "Isolation and characterizat cGMP-stimulated 3',5'-cyclic nucleotide ph (1997)						
C42	Sambrook, et al., "Hybridization of Radiola Acids," Molecular Cloning: A Laboratory Laboratory Press: Cold Spring Harbor, Ne	Manual, Cold Spi	ring Harbor	Nucleic			
C43	Schudt, et al., "Analysis of PDE4 Isoenzyn Pharmacological Methods," <u>Phosphodiester</u> York, New York pp. 21-40 (1996)			- 13			
C44	Sertie, et al., "A gene which causes severe encephalocele (Knobloch syndrome) is map 5:843-847 (1996)		-				
C45	Verma, "Treatment of disease by introducing becoming feasible. But the therapy will not can be coaxed to work throughout life," Sci.	t reach its full pote	ential until th				

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

ÓSURE STATEMENT

Atty Docket No. 27866/37993 Serial No 10/034,015

Applicant

Kate Loughney

Filing Date 12-20-01 Group 1652

(Use several sheets if necessary)

SER SCHILL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C46 Vallada, et al., "Linkage studies in bipolar affective disorder with markers on chromosome 21," J. Affect. Disord. 41:217-221 (1996) Veske, et al., "Autosomal recessive non-syndromic deafness locus (DFNB8) maps C47 on chromosome 21q22 in a large consanguineous kindred from Pakistan," Hum. Mol. Genet. 5:165-168 (1996) C48 Yu, et al., "Identification and Characterisation of a Human Calmodulin-Stimulated Phosphodiesterase PDE1B1," Cell Signaling 9:519-529 (1997) C49 Fisher, et al., "Isolation and Characterization of PDE9A, a Novel Human cGMPspecific Phosphodiesterase*," Journal of Biological Chemistry 273:15559-15564 (1998)Mukai, et al., "Separation and characterization of a novel isoenzyme of cyclic C50 nucleotide phosphodiesterase from rat cerebrum," Br. J. Pharmacol. 111:389-390 (1994)Soderling, et al., "Identification and Characterization of a Novel Family of Cyclin C51 Nucleotide Phosphodiesterases*," Journal of Biological Chemistry 273:15553-15558 (1998)

EXAMINER

DATE CONSIDERED